Your browser doesn't support javascript.
loading
Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study.
Tank, Jaydeep; Gupte, Sanjay; Mahapatra, Purna Chandra; Reddy, Jayanthi; Mittal, Pratima; Mukhopadhyay, Ashish Kumar; Vyas, Lila; Batra, Achla; Gupta, Mahesh; Tandulwadkar, Sunita; Chandra, Sunita; Bhat, Vidya; Bapat, Kawita; Tank, Parikshit; Kulkarni, Ketan; Swami, Onkar.
  • Tank J; Ashwini Maternity and Surgical Hospital Mumbai India Ashwini Maternity and Surgical Hospital, Mumbai, India.
  • Gupte S; Gupte Hospital and Centre for Research in Reproduction Pune - Obstetrics and Gynecology PuneMaharashtra India Gupte Hospital and Centre for Research in Reproduction, Pune - Obstetrics and Gynecology, Pune, Maharashtra, India.
  • Mahapatra PC; Prachee Nursing Home Cuttack India Prachee Nursing Home, Cuttack, India.
  • Reddy J; J. J. Hospital Hyderabad India J. J. Hospital, Hyderabad, Hyderabad, India.
  • Mittal P; Vardhman Mahavir Medical College and Safdarjung Hospital New Delhi India Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
  • Mukhopadhyay AK; CSS College of Obstetrics Kolkata India CSS College of Obstetrics, Gynae. & Child health, Kolkata, India.
  • Vyas L; Vyas Clinic JaipurRajasthan India Vyas Clinic, Jaipur, Rajasthan Jaipur, India.
  • Batra A; Vardhman Mahavir Medical College and Safdarjung Hospital New Delhi India Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
  • Gupta M; Pushpam Hospital Ahmedabad India Pushpam Hospital, Ahmedabad, India.
  • Tandulwadkar S; Ruby Hall Clinic IVF and Endoscopy Centre Pune India IVF and Endoscopy Centre, Ruby Hall Clinic, Pune, India.
  • Chandra S; Rajendra Nagar Hospital and IVF Center Lucknow India Rajendra Nagar Hospital and IVF Center, Lucknow, India.
  • Bhat V; Radhakrishna Multispecialty Hospital BangaloreKarnataka India Radhakrishna Multispecialty Hospital, Bangalore, Karnataka, India.
  • Bapat K; Bapat Hospital IndoreMadhya Pradesh India Bapat Hospital, Indore, Madhya Pradesh, India, Indore, India.
  • Tank P; Ashwini Maternity and Surgical Hospital Mumbai India Ashwini Maternity and Surgical Hospital, Mumbai, India.
  • Kulkarni K; Emcure Pharmaceuticals PuneMaharashtra India Emcure Pharmaceuticals, Pune, Maharashtra, India.
  • Swami O; Emcure Pharmaceuticals PuneMaharashtra India Emcure Pharmaceuticals, Pune, Maharashtra, India.
Article en En | MEDLINE | ID: mdl-38765536
ABSTRACT

Objective:

Despite the literature on dydrogesterone, studies on dydrogesterone utilization patterns are largely lacking in Indian patients.

Methods:

This was a multi-center, retrospective, observational, cross-sectional, and descriptive study across 817 centers in India. Data of patients who received dydrogesterone in past and provided consent for future use of their medical record for research purpose was were retrieved and analyzed.

Results:

Data of 7287 subjects (aged 29.55±4.84 years) was analyzed. Threatened abortion was the most common indication for which the subjects received dydrogesterone (46.9%) followed by recurrent pregnancy loss. Polycystic ovary syndrome (PCOS), thyroid disorders and anemia were the most common comorbid conditions and prior pregnancy loss, advanced maternal age and obesity were the most common risk factors seen in subjects who received dydrogesterone. Total 27.5% of subjects received a loading dose of dydrogesterone, and majority (64%) received 40 mg as loading dose. 10 mg dose was used as maintenance or regular dose in 81.4% of the subjects. Twice daily (BID) was the most common dosing frequency (66.6%). The most common concomitant medications being taken by the subjects on dydrogesterone included folic acid (45.1%), iron supplements (30.3%) and calcium and vitamin D3 supplements (25.5%). Another progesterone preparation (oral, injection, vaginal, tubal) other than dydrogesterone was used concurrently in 7.8% of subjects.

Conclusion:

The study helped to identify the patient population that is benefitted by dydrogesterone and the preferred indications, risk factors, comorbid conditions and concomitant medication used in this patient population at real-life scenario.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Progestinas / Didrogesterona Límite: Adult / Female / Humans / Pregnancy País como asunto: Asia Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Progestinas / Didrogesterona Límite: Adult / Female / Humans / Pregnancy País como asunto: Asia Idioma: En Año: 2024 Tipo del documento: Article